Decision on C(2021) 8740(final) of 26 November 2021 amending the conditional marketing authorisation granted by Decision C(2020) 9598(final) for “Comirnaty - tozinameran, COVID-19 mRNA vaccine (nucleoside-modified)”, a medicinal product for human use

This procedure concerns an objection to a European Commission decision to amend the marketing authorisation for the COVID-19 vaccine Comirnaty. It relates to the vaccine's authorisation as a medicinal product for human use.

This objection affects the authorisation process for the Comirnaty vaccine. It is relevant to public health and the regulatory framework for medicines within the EU.